Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors

被引：0
|
作者：
Bendell, Johanna C.
Hart, Lowell L.
Pant, Shubham
Infante, Jeffrey R.
Jones, Suzanne Fields
Mohyuddin, Adil
Murphy, Patrick
Patton, Jeffrey
Penley, William Charles
Thompson, Dana Shelton
Burris, Howard A.
机构：
[1] PLLC, Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[2] Florida Canc Specialists SCRI, Ft Myers, FL USA
[3] Stephenson Canc Ctr SCRI, Oklahoma City, OK USA
[4] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.475
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
475
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors
    Pant, Shubham
    Hart, Lowell L.
    Bendell, Johanna C.
    Infante, Jeffrey R.
    Jones, Suzanne Fields
    Mohyuddin, Adil
    Murphy, Patrick
    Patton, Jeffrey
    Penley, William Charles
    Thompson, Dana Shelton
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Jones, Suzanne F.
    Hart, Lowell
    Pant, Shubham
    Moyhuddin, Adil
    Lane, Cassie M.
    Earwood, Chris
    Murphy, Patrick
    Patton, Jeffrey
    Penley, William C.
    Thompson, Dana
    Infante, Jeffrey R.
    CANCER INVESTIGATION, 2015, 33 (10) : 477 - 482
  • [3] Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
    Toshihiko Doi
    Yusuke Onozawa
    Nozomu Fuse
    Takayuki Yoshino
    Kentaro Yamazaki
    Junichiro Watanabe
    Mikhail Akimov
    Matthew Robson
    Narikazu Boku
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 629 - 636
  • [4] Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Onozawa, Yusuke
    Fuse, Nozomu
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Watanabe, Junichiro
    Akimov, Mikhail
    Robson, Matthew
    Boku, Narikazu
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 629 - 636
  • [5] A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies
    Sessa, C.
    Sharma, S. K.
    Britten, C. D.
    Vogelzang, N. J.
    Bhalla, K. N.
    Mita, M. M.
    Pluard, T. J.
    Stiegler, P.
    Quadt, C.
    Shapiro, G. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors
    Bendell, Johanna C.
    Bauer, Todd M.
    Lamar, Ruth
    Joseph, Mathew
    Penley, William
    Thompson, Dana S.
    Spigel, David R.
    Owera, Rami
    Lane, Cassie M.
    Earwood, Chris
    Burris, Howard A., III
    CANCER INVESTIGATION, 2016, 34 (06) : 265 - 270
  • [7] First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
    Sessa, Cristiana
    Shapiro, Geoffrey I.
    Bhalla, Kapil N.
    Britten, Carolyn
    Jacks, Karen S.
    Mita, Monica
    Papadimitrakopoulou, Vali
    Pluard, Tim
    Samuel, Thomas A.
    Akimov, Mikhail
    Quadt, Cornelia
    Fernandez-Ibarra, Cristina
    Lu, Hong
    Bailey, Stuart
    Chica, Sandra
    Banerji, Udai
    CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3671 - 3680
  • [8] A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
    D. J. Renouf
    D. Hedley
    M. K. Krzyzanowska
    M. Schmuck
    L. Wang
    M. J. Moore
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 541 - 545
  • [9] Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma
    Kosovec, Juliann E.
    Zaidi, Ali H.
    Kelly, Lori A.
    Rotoloni, Christina L.
    Vytlacil, Christopher
    DiCarlo, Christina
    Matsui, Daisuke
    Komatsu, Yoshihiro
    Boyd, Natalie H.
    Omstead, Ashten
    Kolano, Elena L.
    Biederman, Robert W. W.
    Finley, Gene
    Silverman, Jan F.
    Landreneau, Rodney J.
    Jobe, Blair A.
    ANNALS OF SURGERY, 2016, 264 (02) : 297 - 304
  • [10] A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
    Renouf, D. J.
    Hedley, D.
    Krzyzanowska, M. K.
    Schmuck, M.
    Wang, L.
    Moore, M. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 541 - 545
12345